Experienced and Innovative Management

Paul Kinnon
Paul KinnonPresident and Chief Executive Officer
Mr. Kinnon has served as our President and Chief Executive Officer and a Director since September 2013. Mr. Kinnon has more than 20 years of global leadership experience in innovative life science and diagnostics companies. From January through August 2013, he provided consulting services to the life science sector as a Partner at Arch Global Research. During a portion of this time, Mr. Kinnon provided consulting services to us. From January 2007 to December 2012, Mr. Kinnon was President, Chief Executive Officer and a Director of ZyGEM Corporation Limited, a biotechnology company, where he transformed the company from a regional enzyme provider into a leader in integrated microfluidic technologies for forensic and clinical diagnostic applications. From May 2006 to June 2007, Mr. Kinnon was Vice President & General Manager Environmental Diagnostics (later expanded to Applied Markets) at Invitrogen Corporation (now Life Technologies), a high growth life sciences and diagnostics firm, and from October 2004 until April 2006, he was Vice President, Global Strategic Alliances at Invitrogen. Previously, Mr. Kinnon also held business, sales and marketing roles of increasing responsibility at Guava Technologies, Inc., Cellomics, Inc. and other life science companies. Mr. Kinnon earned his Bachelor of Sciences degree in Applied Chemistry at Coventry University in the United Kingdom and holds a Diploma of Marketing. The Board selected Mr. Kinnon to serve as a director because he is our Chief Executive Officer and because of his expansive knowledge and experience in the life science industry, as well as his past executive management roles at both life science and biotechnology companies.
Leon Richards
Leon RichardsChief Accounting Officer
Mr. Richards joined Transgenomic in 2012 as Corporate Controller. In November 2014, Mr. Richards was appointed Chief Accounting Officer. In this role, Mr. Richards is responsible for providing strategic direction to Transgenomic’s finance groups, including directing the corporate accounting functions and practices, maintaining its fiscal records, and preparing its financial reports. He also oversees the design and operation of the Company’s system of internal controls, ensuring compliance with the rules and regulations of Sarbanes-Oxley Act.

Prior to joining Transgenomic, Mr. Richards had approximately 30 years of experience directing all accounting functions for the financial group at public companies across various industries. Most recently, he was Controller and Chief Accounting Officer at Baldwin Technology company Inc, a leading global supplier of process automation equipment for the printing and publishing industry. Earlier in his career Mr. Richards was Director of Financial Reporting and Control at Ciba Specialty Chemicals (now BASF), and he also held positions of increasing responsibility in the financial group at Hercules, Inc., (now Ashland Chemical), a New York Stock Exchange-listed firm. Mr. Richards started his career in public accounting at KPMG.

Mr. Richards received his B.B.A. in Accounting from Iona College and is a certified public accountant.

Joanne Lewis
Joanne LewisVice President, Human Resources
Ms. Lewis joined Transgenomic in June 2013 with over 10 years experience in the healthcare industry. Ms. Lewis serves on the Transgenomic Executive Committee. In her role, she leads Transgenomic’s worldwide human resources strategy. Her key focus areas include enterprise talent management and succession planning, leadership development, diversity and inclusion, executive compensation, and organizational effectiveness for employees worldwide.

Prior to joining Transgenomic, Ms. Lewis served as Director, Human Resources at Covidien’s Surgical Solutions Business, global health care products company and manufacturer of medical devices and supplies. Prior to that she held a series of HR leadership roles of increasing responsibility at Bayer HealthCare Pharmaceuticals Inc.
Ms. Lewis received her M.S. in Industrial Relations and B.S. in Personnel Management from the University of New Haven.

Steve Miller
Steve MillerSenior VP & GM Patient Testing
Mr. Miller joined Transgenomic in 2013 as SVP & General Manager Patient Testing and serves on the Transgenomic Executive Committee. In this role, Mr. Miller has global responsibility for all aspects of the CLIA patient testing business to include revenue, profitability, operations, bioinformatics, commercial and revenue cycle management.

Mr. Miller has over 20 years experience in the diagnostic and biotechnology sectors, with in-depth experience in developing and implementing business strategies. Mr. Miller also has broad experience successfully leading reimbursement, sales, marketing and operations. Prior to joining Transgenomic, Mr. Miller provided consulting services to several diagnostic and biotechnology companies. Mr. Miller held the positions of Chief Commercial Officer at BG Medicine where he led the early commercialization of that company’s cardiac diagnostic assay Galectin-3 and President and Chief Commercial Officer at Mira Dx. He also held a variety of key positions within Athena Diagnostics with responsibilities for reimbursement, corporate accounts, business development, marketing and sales. His last position with Athena was as the Vice President of Sales & Marketing as that company grew from $6 million to over $100 million in sales.

Mr. Miller received a B.A. in Business Psychology from Miami University.